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With the development of novel treatments for autoimmune disorders, it has become a popular research focus which 
mesenchymal stem cells (MSCs) have the capacity to counteract with autoimmune diseases progression. One of the 
underlying mechanisms behind their activities is the release of extracellular vesicles especially exosomes. MSC-derived 
exosomes are hypoimmunogenic nanocarriers which contain numerous immunoregulatory factors and similar to other 
exosomes, are able to pass through boundaries like the blood-brain barrier (BBB). Accumulating evidence provided 
by animal studies has demonstrated that MSC-derived exosomes, as a novel therapy, can re-induce self-tolerance, with-
out subsequent complications reported for other treatments. Therefore, therapeutic applications of MSC-derived exo-
somes are contributing to core advances in the field of autoimmune diseases. Here, we briefly describe the biological 
characteristics of MSC-derived exosomes and review the experimentally verified outcomes for autoimmune disease ther-
apy purposes.
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Introduction 
  Mesenchymal stem cells (MSCs) are multipotent, self- 
renewable, and spindle shape cells (1) which were firstly 
isolated from guinea-pig bone marrow and spleen by 
Friedenstein et al. in 1970 (2). Now, MSCs can be isolated 
from cord blood, umbilical cord, bone marrow, adipose tis-
sue, and many other tissues (3, 4). The single connecting 
feature of all these tissues is the presence of perivascular 
space around the blood vessels where pericytes come off 
and differentiate into MSCs after vessels got inflamed or 
injured. According to their common origin, pericytes and 
MSCs both are negative for CD34, CD45, CD56 and pos-
itively express CD29, CD44, CD73, CD90, CD105, CD146 
(5-7). MSCs are functionally defined based on their ca-
pacity to produce molecules that provide a regenerative 
and immunoregulatory milieu. Moreover, these multi-
potent cells can differentiate into a closely related family 
of cells in vitro or following transplantation and sub-
sequently recover the damages. However, recent findings 
have reported that MSCs do not significantly differentiate 
into other lineages in vivo under normal condition (8). 
Consequently in a new paradigm, Arnold Caplan coined 
“Medical Signaling Cell” for MSCs to precisely express 
that mesenchymal stem cells dock at the sites of injury 
and produce regenerative and immunoregulatory compo-
nents (9, 10). Afterwards, a great number of clinical trials 
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Graphical Abstract. Mesenchymal exosomes have been newly used to address impaired immune responses in some animal models of auto-
immune diseases. Clinical experiments demonstrated that these vesicles successfully recover immune balance of autoreactive cells. The 
current picture highlights the main beneficial outcomes achieved from in vivo evaluation of MSC-derived exosomes in the mouse models.
have exploited MSC-based modalities in clinical con-
ditions such as Type 1 diabetes mellitus, Rheumatoid 
Arthritis (RA), Multiple Sclerosis (MS), Crohn’s disease, 
Lupus, kidney transplant, Graft versus Host Disease 
(GvHD) and many cancers (clinicaltrials.gov).
  Unlike other stem cells (embryonic stem cells as well 
as induced pluripotent stem cells), MSCs have a dynamic 
immunomodulatory profile which lies on their ability to 
sense the injury or inflammation and then switch to the 
required response (11). For instance, MSCs produce trans-
forming growth factor beta (TGF-β), indoleamine 2,3-di-
oxygenase (IDO), nitric oxide (NO), soluble HLA-G, and 
prostaglandin E2 (PGE2) in response to high concen-
tration of interferon gamma (IFNγ), tumor necrosis fac-
tor alpha (TNF-α), and toll like receptor 3 (TLR3) ago-
nists (11-13). This reaction activates CD4＋CD25hiFoxP3＋ 
regulatory T cells (Tregs) while inhibits natural killer cell 
and T cell responses (11-13). In contrast, low level of in-
flammatory agents and TLR4 agonists, decrease IDO, NO, 
PGE2 production and increase expression of pro-in-
flammatory cytokines (CXCL9, CXCL10, MIP-1α, MIP-1β, 
CCL5), indicating their double-edged sword function 
within the immune system (14). Accumulating inves-
tigations have demonstrated that these factors are mainly 
delivered through direct secretions of soluble molecules 
and release of extracellular vesicles particularly exosomes. 
Exosomes
  As shown in Table 1 (15-20), exosomes are one of the 
nanoscale cell-derived extracellular vesicles (EV) with 30∼
100 nm diameter (15). Exosomes were first thought to be 
required for discarding unnecessary proteins out of the 
cells and termed as “garbage cans” (21). Later, they were 
introduced as gulps of cytosol delivering bioactive mole-
cules especially proteins and small RNAs (like micro-
RNAs) in intercellular communications. Recent inves-
tigation have shown that exosomes transfer bioactive mol-
ecules among cells and therefore is able to play an essen-
tial role in pathological conditions including Alzheimer’s 
disease (22), transmissible spongiform encephalopathies 
(23), Parkinson’s disease (24), and amyotrophic lateral 
sclerosis (25) or could be employed as nanoscale platforms 
for drug delivery.
  Constitutive shedding of exosomes is mostly reported 
for immune cells (i.e. MSCs, lymphocytes, mast cells and 
dendritic cells) and non-immune cells particularly tumor 
cells (26, 27). Additionally, interaction between T lympho-
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Table 1. Commonalities and diversities of EVs
Features\Type of 
vesicle 
Exosome Ectosome or Microvesicle or Microparticle Apoptotic body
The most frequent 
biomarkers 
CD9, CD63, CD81 (15), Alix (16), 
Tsg101 (16, 17) 
No common marker (18) Annexin V, Phosphatidylserine,
Thrombospondin, C3b (19)
Size (nm) 30∼100 100∼1000 500∼4000
Stemed from Intraluminal microvesicles which 
are originated from endosomal 
pathway, pass through plasma 
membrane via exocytosis
Plasma membrane budding of activated 
cells including human neutrophils, tumor 
cells, erythrocytes, and polymorpho-
nuclear leukocytes (20)
Plasma membrane of apoptotic 
cells containing cell fragments 
Table 2. The content of mesenchymal-derived exosomes
Component(s) Function(s) Source(s) Reference(s)
hCAP-18/LL-37 Antibacterial hMSC (35)
SOX2, Nanog, POU5F1A/B Critical role in multipotency of MSC hMSC (36)
Transforming Growth 
Factor β1 (TGF-β1)
Inhibits lymphocyte proliferation and differentiation hMSC (37, 38)
Interleukin 6 (IL-6) IL-10 and inducer
Acute phase reaction enhancer
hMSC (38)
Interleukin 10 (IL-10) T cell proliferation suppressor
Regulatory T cell inducer
pMSC (39)
Hepatocyte Growth Factor 
(HGF)
Decrease antigen presenting capacity of Dendritic cells and suppress 
T cell response 
hMSC (40, 41)
PGE-2 T cell proliferation suppressor
NK cell proliferation suppressor
hMSC (42)
miR-155 Pro and anti-inflammatory miRNA based depending on stimulant 
involved
mMSC (43)
miR-146a Anti-inflammatory miRNA hMSC (36)
miR-181c Negatively affects NF-κB importin on nuclear membrane hMSC (44)
miR-17 Anti NLRP3 inflammasome signaling pathway
Targets E-selectin
hMSC, mMSC (36, 45)
miR-21 Anti TLR4 signaling pathway hMSC (36, 46)
miR-10a Endothelial inflammation and senescence regulator hMSC (36)
miR-92a Targets MKK4 kinase upon TLR signaling pathway in macrophages hMSC (36)
miR-99b Downregulates expression of IL-1β, IL-6, and IL-12 by targeting either 
TNF-α and TNF-α superfamily member 4 receptor genes
hMSC (36)
hMSC: human-derived MSC, mMSC: mouse-derived MSC, pMSC: porcine-derived MSC.
cytes and antigen presenting cells strongly induce the re-
lease of the exosomes bearing TCR/CD3/zeta complex 
(28) and MHC II-peptide (29), respectively. It was lately 
demonstrated that in hypoxic preconditioning and pres-
ence of lipopolysaccharide, MSCs significantly enhance 
the release of exosomes which shuttle anti-inflammatory 
agents to polarize macrophages into the M2 phenotype 
(30, 31). 
  Generally, extracellular vesicles affect the neighboring 
cells via two different strategies: 1) fusion dependent 2) 
fusion independent. The first mechanism takes place 
when vesicle is taken up by a recipient cell. There are two 
types of fusions: 1) direct fusion of the extracellular vesi-
cle with the plasma membrane of recipient cell that re-
quires receptor-ligand interactions 2) Back fusion which 
confers to the endocytosis of vesicle by the recipient cell 
and subsequently incorporation of vesicle with endosome’s 
membrane (32, 33). In fusion independent manner, the 
vesicle and recipient cells interact with each other, like 
when exosomes bearing MHC-peptide are being specifi-
cally attached to the T cell receptor (TCR) on T cells (34).
MSC-Derived Exosome Therapy: Cons and Pros
  As shown in Table 2 (35-46), recent findings depicted 
that MSC-derived exosomes deliver various cytoplasmatic 
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constituents of the MSC secretomes, relevant to the stem-
ness, angiogenesis, and particularly inflammatory factors. 
They were first used in 2010 for regeneration of tissues 
in a mouse model of myocardial ischemia/reperfusion in-
jury (47) and are extensively on investigations at present. 
As a cell-free therapeutic tools provided a potential oppor-
tunity to unlock existing boundaries of cell therapy for au-
toimmune diseases. Exosomes introduce several advan-
tages including capacity to cross the barriers (blood-brain 
barrier, capillaries) (48) and small enough to evade from 
being cleared by reticuloendothelial system (RES) (49). In 
addition to their general characteristics, MSC-derived exo-
somes are normally hypo-immunogenic due to the lack of 
MHC-II and low expression of MHC-I similar to their pa-
rental cells (50). It has also been revealed that MSCs can 
produce higher amount of exosomes compared with hu-
man cell lines like human embryonic kidney (HEK) and 
human acute monocytic leukemia (THP-1); Therefore, 
MSCs appear to be one of the best sources for high 
amount of immunoregulatory exosomes (51, 52). 
  Despite therapeutic advantages of MSC-derived exo-
somes, quantification of their protein profile and more im-
portantly durability of cryopreserved exosomes as well as 
their in vivo tracking are still effortful. Regarding frozen 
exosomes, Cosenza et al. (53) analyzed functions of cry-
opreserved MSC-derived exosomes compared to freshly 
isolated exosomes and demonstrated that storage destabi-
lize the integrity of membrane, leading to leakage of its 
content, aggregation of vesicles, and decrease in their im-
munosuppressive capacity. MSC-derived exosomes ob-
viously express both the common MSC markers, such as 
CD44, CD90, and CD73 and markers of exosomes, CD9, 
CD63, and CD81 (51). These markers are used to track 
exosomes especially for drug delivery. Alternatively, cell 
tracing dyes can also help to chase exosomes in vivo. For 
instance, intravenous (i.v.) administration of Vybrant Cell 
Tracer DiD- or DiI-labeled exosomes to the mouse model 
of acute kidney injury, were used to monitor accumulation 
of MSC-derived exosomes. In this investigation, exosomes 
were mostly found in kidney, spleen, liver, and lung as 
filtering organs of the body (54). Apart from utilization 
of fluorescent molecules to chase organ localization of 
EVs, lower sensitivity of fluorophores negatively affect 
pharmacokinetic analysis of their applications (especially 
for quantification of exosome accumulated in a target tis-
sue) (55). Radiolabeling with iodine-125 and biolumi-
nescence emitted from luciferase provide a more practical 
solution for whole-body imaging of exosome-treated ani-
mals with significantly higher sensitivity of detection (56, 
57). Also, stability of B16-BL6 melanoma cell-derived exo-
somes in blood circulation were evaluated using exosomes 
expressing a fusion protein of Gaussia luciferase-Lacta-
dherin, a reporter protein attached to one of the exosome’s 
trophic protein, respectively. The results indicated exoso-
mal half-life of about 2 minutes following i.v. injection. 
This finding suggests short half-life of exosomes is be-
cause of their fast uptake by liver and spleen resident 
macrophages (56). 
MSC-Derived Exosome Therapy for Autoimmune 
Diseases
  Utilization of the MSC-derived exosomes for auto-
immune diseases therapy is at early stages. Most of studies 
are focused on immunomodulatory effects of these small 
vesicles in animal models. Here we will discuss the roles 
of these exosomes in the treatment of autoimmune disea-
ses. 
Multiple Sclerosis
  Multiple Sclerosis (MS) is a chronic autoimmune dis-
ease characterized by neuroinflammation and demyelina-
tion in the central nervous system (CNS) (58). Numerous 
studies have revealed activation and recruitment of au-
toaggressive CD4＋ and CD8＋ T cells into the CNS as the 
main pathogenic players of MS (59, 60). Disease-modify-
ing treatments (DMTs) especially IFN-β are commonly 
prescribed to treat the affected individuals (61, 62). 
Despite their beneficial impacts, DMTs increase the risk 
of adverse effects including lymphopenia, lymphadenop-
athy, dyspnea and lipoatrophy (63-65). Hence, identi-
fication and evaluation of alternative approaches with low-
er side effects are necessary.
  We have already demonstrated that MSCs and their ac-
tivity have been altered after DMT consumption in relaps-
ing-remitting MS patients (66). Indeed, patients own stem 
cells may have more deficiencies which not efficiently pre-
vent for MS initiation and progression (67). However, 
MSCs can differentiate into neural cells and release neuro-
trophic molecules, indicating their strong neuroprotective 
effects for treating MS (68). Accumulating evidence has 
shown that MSCs can regulate autoreactive cells in a para-
crine manner through secretion of inhibitory cytokines or 
molecules as well (69-71). MSC-derived exosomes can also 
induce peripheral tolerance toward autoreactive T cells via 
transferring the tolerogenic molecules to the autoreactive 
immune cells.
  Since exosomes are lipid-bound nano-vesicles, they can 
cross the blood-brain barrier. Therefore, incubation of 
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exosomes in presence of neurotrophic and remyelination 
factors elevate their therapeutic profits. Additionally, ex-
pression of receptor(s) with ability to recognize neural 
markers in the MSCs increase efficiency of the delivery 
system. In this case, Zhuang et al. (72) have administered 
exosomes bearing anti-inflammatory compounds such as 
curcumin to the EAE mouse and demonstrated that clin-
ical symptoms of the diseases were improved. 
  In 2012, Mokarizadeh et al. (73) showed that MSC-de-
rived extracellular vesicles exert immunomodulatory ef-
fects on splenic mononuclear cells (MNCs) of EAE mouse. 
These small vesicles not only reduced autoreactive lym-
phocytes proliferation, but also potentially induced MNCs 
to secrete significant amount of IL-10. They also demon-
strated that MSC-derived vesicles contain PD-L1, ga-
lectin-1, and TGF-β, which help them with their im-
munoregulatory functions. This investigation proposed 
that MSC-derived vesicles including exosomes are capable 
of transferring anti-inflammatory molecules into autor-
eactive cells and re-inducing a self-tolerance. Later in 
2018, Laso-García et al. (74) revealed that i.v. admin-
istration of MSC-derived exosomes to a progressive model 
of MS, Theiler’s murine encephalomyelitis virus (TMEV)- 
induced demyelinating disease, recovered the disabilities 
observed before treatment. They indicated that adminis-
trated MVs prompt remyelination, reduce the brain atro-
phy, and infiltration of inflammatory CD4＋ T cells to the 
spinal cord of TMEV-infected mice. 
  Recently, Li et al. (75) demonstrated that MSC-derived 
exosomes polarize microglia cells mainly into the M2 phe-
notype and consequently alleviate clinical scores of EAE. 
In this study, the balance of M1/M2 in EAE rates sig-
nificantly deviated toward M2 phenotype and their cyto-
kines profile (IL-10 and TGF-β), while frequency and ac-
tivity of M1 cells were decreased. Interestingly for the first 
time, Hosseini Shamili et al. (76) bioconjugated the 
MSC-derived exosomes to an aptamer which targets oligo-
dendrocyte markers. The armed exosome improved pro-
liferation of oligodendroglia cell line (OLN93) in vitro and 
reduced both inflammatory responses and demyelinated 
lesions in the CNS of EAE mice. These methodologies 
may provide a new perspective toward indirect applica-
tions of MSCs in the treatment of MS. 
Rheumatoid Arthritis
  Rheumatoid arthritis (RA) is an inflammatory disease 
with unknown etiology that causes articular destruction 
and subsequently functional loss in joints. RA immuno-
pathogenesis is characterized by disordered innate and 
adaptive immunity that result in immune complex-med-
iated complement activation, autoreactive lymphocyte re-
sponse against self-antigens, and also dysregulated cyto-
kine networks (77, 78). 
  As with MS, there are various biological disease-modify-
ing anti-rheumatic drugs (bDMARDs) available to control 
the symptoms of RA. For example, blockade of proin-
flammatory cytokines including GM-CSF, TNF-α, and 
IL-6 with antibodies or soluble decoy receptors have been 
mainly utilized for patients suffering from RA for many 
years (79). Along with beneficial effects of immunosup-
pressive and immunomodulatory drugs, they present vari-
ous side effects including nausea, liver problems, lympho-
penia, high risk of infection, and etc. (79). There is indeed 
a crucial need for new treatment modules with fewer side 
effects. MSC-derived exosomes have been considered to 
exert immunosuppressive activities, supporting their ap-
plication in rheumatic diseases. Although the use of exo-
somes derived from various origins have been studied ex-
tensively to date (80, 81), to date, the role of MSC-derived 
exosomes is still in the beginning.
  In 2018, Cosenza et al. (53) showed that MSC-derived 
exosomes reveal anti-inflammatory impacts on T and B 
lymphocytes in collagen-induced arthritis (CIA) mice 
model. In this study, MSCs-derived exosomes effectively 
inhibit T lymphocyte proliferation in a dose-dependent 
manner and decreased the percentage of mature T and B 
cell subsets. Interestingly, exosomes increased regulatory 
T cell populations much better than MSCs and MSC-de-
rived microvesicles. Further investigations confirmed that 
microvesicles derived from MSCs are less effective to in-
duce TGF-β and IL-10 production in T and B lympho-
cytes compared to MSCs alone (82). In 2018, Chen et al. 
(83) demonstrated that modified MSC-derived exosomes 
which contain miRNA-150, target the matrix metal-
loproteinase 14 (MMP14) and thereafter, decrease migra-
tion and invasion of fibroblast-like synoviocytes (FLS). 
They also indicated that injection of these engineered exo-
somes to the CIA mouse can effectively reduce the hind 
paw thickness and the clinical arthritic scores of animals. 
Another study evaluated beneficial impacts of human um-
bilical cord mesenchymal stem cells-derived exosomes 
(hUCMSC-derived exosomes) on bone destruction in CIA 
rats. Interestingly, the treatment reduced recruitment of 
inflammatory cell to the joints and prevent from joint 
synovial hyperplasia. The authors proposed that the un-
derlying mechanism could be due to regulating of the im-
balance of RANKL/OPG. To be clear, they showed that 
RANKL was decreased in serum and synovial tissues of 
the CIA rats, while the treatment raised the OPG concen-
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tration (84). In consensus with this study, another group 
demonstrated that intra-articular injection of hUCMSC- 
derived exosomes significantly decreased autoreactive in-
filtering chemokines CCL2 and CXCL12 in serum and 
synovial fluid (85). 
Type 1 Diabetes Mellitus (Insulin-Dependent 
Diabetes Mellitus) 
  Type 1 diabetes mellitus (T1DM) is an incurable and 
chronic autoimmune disease which is classically identified 
by reduced level of insulin due to autoimmune destruction 
of insulin-producing pancreatic β cell, leading to hyper-
glycemia (86). Although underlying mechanism of disease 
is unknown, disruption of immune tolerance in autor-
eactive B cells, CD4＋ T cells and particularly CD8＋ cyto-
toxic T lymphocytes (CTL) are believed to contribute to 
the pathogenesis of type 1 diabetes. As a result, diabetic 
patients need exogenous insulin regiment to control their 
blood glucose level and avoid from consequences caused 
by hyperglycemia like fatigue, cataract, and also diabetic 
coma. Repetitive injection of insulin point to the fact that 
insulin titer is not stable in affected subjects and patients 
require a durable cure for diabetes. 
  In order to develop novel therapies for T1DM, re-
searchers have taken different approaches so far. Since 
first whole pancreas transplantation in 1966, long-term 
normoglycemia has been achieved with a graft survival 
rate of 50 to 70 % after 5 years (87, 88). But sequential 
complications including pancreatitis, thrombosis, and 
pseudocyst appeared in graft are major disadvantages of 
this surgery (89). Eventually, transplantation of endocrine 
part of pancreas (known as islet transplantation) is a 
well-developed procedure to minimize complications of in-
sulin therapy and pancreas transplantation (90). last two 
methods prevent from the disease progression for a lim-
ited period of time, but can not correctify autoimmune re-
sponse against the β cells. The cure must be in the region 
where autoimmune response is originated. 
  Various strategies have been applied to recover immune 
tolerance at critical points of regulatory pathways. Of the 
different approaches, anti-CD3 antibodies nonspecifically 
induce T cell anergy by co-stimulation blockade. Thereaf-
ter, beta cells are preserved in disease established non- 
obese diabetic (NOD) mice (91). Traditional αCD3 anti-
bodies like OKT3 were provided from mouse and could 
not be administered continuously for chronic diseases. 
This drawback is overwhelmed by humanizing the anti-
body sequence (92). Moreover, mitogenic effect of CD3 
specific antibodies on T cells, owning to their cross-link-
ing ability to bind to the Fc receptors on natural killer 
cells and monocytes, brings about a notable cytokine re-
lease (93). This problem can be solved via engineering of 
C-terminal sequence of antibody to stop its binding possi-
bility to Fcγ receptors.
  MSC therapy has also shown antidiabetic effects to re-
store immune response balance in pancreas. Ezquer et al. 
(94) injected GFP expressing MSCs to diabetic mouse and 
reported normalized Th1/Th2 response in diabetic group 
compared to control. They also traced labeled MSCs after 
7 and 65 days to be sure if MSCs differentiate into beta 
cells and lead to normoglycemia. Surprisingly, they found 
MSCs in heart and secondary lymphoid organs (like 
Payer’s patch, inguinal lymph node, and pancreatic lymph 
nodes) not in pancreas. It suggests that the antidiabetic 
effect of MSC is due to its endocrine activity not differ-
entiation capacity. In 2016, Nakano et al. (95) have used 
MSC-derived exosomes to diminish cognitive impairments 
of diabetic rats by repairing damaged astrocytes and more 
importantly neurons. Furthermore, administration of 
MSC-derived exosomes simultaneously with islet trans-
plantation, suppressed proliferation of PBMCs, improved 
regulatory T cell activities and increased graft survival in 
syngeneic mouse model of T1DM (96). Similar to previous 
studies, a group of scientists also evaluated immunomodu-
latory effects of MSC-derived exosomes compared with 
control and reported significant increase of regulatory T 
cell population among splenic MNCs, accompanied by up-
regulation of IL-4, IL-10, TGF-β plus downregulation of 
IL-17 and IFNγ cytokines after treatment. Accordingly 
treatment stabilized the blood glucose and vanished the 
signs of diabetes (97).
Uveitis
  Uveitis is an autoimmune disorder which causes severe 
visual disability (98). Current clinical treatment includes 
corticosteroids, other immunosuppressive drugs, and new-
ly developed biologics. The long-term utilization of each 
is followed by serious systemic side effects and the local 
risk of cataracts and glaucoma (99, 100). Hence, most in-
vestigation intended to find localized and specific 
therapies. Although, it has been recently revealed that i.v. 
injection of MSCs improved experimental autoimmune 
uveitis (EAU) in animal model of uveitis (101-103), the 
underlying mechanisms of MSCs is not clear yet. In 2017, 
Bai et al. (104) showed that, human umbilical cord 
MSC-derived exosomes can reduce the severity of EAU. 
They demonstrated that MSC-derived exosomes inhibited 
the infiltration of inflammatory leukocytes to the eyes and 
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these outcomes could, at least partly, be due to expression 
of CD73 on the MSCs. As expected, exosomes bearing 
CD73 interact with CD39 on activated immune cells and 
induce production of adenosine which result in pro-
liferation inhibition. This study is the only study on the 
role of exosomes uveitis, indicating the importance of fur-
ther investigation in this field. 
Conclusions 
  Until last decade, the contribution of MSC-derived exo-
somes in the control of inflammatory responses has been 
less clear. As a functional vesicle derived from MSCs, exo-
somes have shown same beneficial impacts of the cell of 
origin, to suppress several autoreactive cells in auto-
immune diseases. Moreover, although mesenchymal-de-
rived exosomes expose immunomodulatory functions by 
self, it seems that engineering these vesicles through add-
ing anti-inflammatory molecules and certain receptors, 
they can specifically target tissue/organ of interest. This 
attitude might consider as a potentially novel candidate 
to treat other autoimmune disorders like spondylitis anky-
losing and scleroderma as well.
  With respect to remaining challenges, more inves-
tigations are required to elucidate unclear aspects of 
cell-free therapy using MSC-derived exosomes in ongoing 
studies.
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